Predictors of Complications and Mortality in Patients with Self-Expanding Metallic Stents for the Palliation of Malignant Colonic Obstruction

Mafalda Sousa  Rolando Pinho  Luisa Proença  Joana Silva  Ana Ponte  Jaime Rodrigues  João Carvalho
Gastroenterology Department, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal

Introduction: Self-expanding metallic stents (SEMS) for palliative purposes in malignant colonic obstruction are an alternative to surgery that has gained popularity over time.

Methods: We performed a retrospective study of patients submitted to SEMS for palliation of obstructing malignant colorectal cancer from 2005 to 2015 to evaluate predictive clinical factors for complications and mortality.

Results: Forty-five patients with high rates of technical and clinical success were included (97.8 and 95.6%, respectively), with complications occurring in 17.8% (8.9% perforations, 4.4% obstructions, and 4.4% migrations). The length of the stenosis was superior in patients with complications \( (p = 0.01) \); 11.1% of patients had a re-intervention (2.2% surgery and 8.9% placement of another SEMS). Relief of obstruction without intervention was maintained until death in 77.8% of patients and in 81.4% of patients who had immediate clinical success. The mortality rate was 37.2% at 30 days, 56.5% at 60 days, and 87.5% at 1 year. There were no predictors of survival identified, including age, sex, tumor stage, metastasis, or complications of the procedure.

Discussion and Conclusions: In this study, SEMS placement was associated with a high rate of technical and clinical success and a low rate of complications, being an option to palliate patients with obstructive neoplasia. The length of the stenosis was associated with a greater risk of complications. The majority of stent-related complications can be managed successfully without surgery.

© 2016 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel

Keywords
Colorectal neoplasms · Endoscopy · Intestinal obstruction · Metals · Palliative care · Stents
**Resumo**

**Introdução:** As próteses metálicas auto-extensíveis (PMAE), como tratamento paliativo na oclusão colo-retal maligna, são uma alternativa à cirurgia que tem ganho popularidade nos últimos tempos. **Métodos:** Estudo retrospectivo de pacientes submetidos a PMAE para palição de cancro colo-retal maligno oclusivo de 2005 a 2015, com o objetivo de avaliar fatores clínicos preditivos de complicações e mortalidade. **Resultados:** Foram incluídos 45 pacientes, tendo-se verificado taxas de sucesso técnico e clínico elevadas (97.8 e 95.6%, respectivamente), com complicações a ocorrem em 17.8% dos pacientes (8.9% perfurações, 4.4% obstruções e 4.4% migrações). O comprimento da estenose foi superior em pacientes com complicações (p = 0.01). 11.1% dos pacientes foram submetidos a uma re-intervenção (2.2% cirurgia e 8.9% colocação de outra PMAE). A resolução da obstrução sem intervenção adicional foi mantida até à morte em 77.8% dos pacientes e em 81.4% daqueles que tiveram sucesso clínico. A taxa de mortalidade foi de 37.2% aos 30 dias, 56.5% aos 60 dias e 87.5% ao ano. Não houve preditores de sobrevida identificados, incluindo idade, sexo, estadiamento do tumor, metástases ou complicações do procedimento. **Discussão e Conclusões:** Neste estudo, a colocação PMAE foi associada a taxas de sucesso técnico e clínico elevadas, com baixo número de complicações, sendo uma opção viável para o tratamento paliativo de doentes com neoplasias obstrutivas. O comprimento da estenose foi associado a um maior risco de complicações. A maioria das complicações relacionadas com a prótese foi resolvida com sucesso sem necessidade de cirurgia.

**Palavras Chave**

Neoplasias colorretais · Endoscopia · Oclusão intestinal · Metais · Cuidados paliativos · Próteses

---

**Introduction**

Colorectal cancer is one of the most common cancers in Western societies, and obstruction is the presenting symptom in 10–30% of patients [1, 2]; 70% of these patients already have advanced disease, and only 50% are candidates for curative surgery at presentation [3, 4].

The traditional treatment for unresectable tumors was diverting colostomy with permanent stoma creation for relieving symptoms of obstruction. Unfortunately, this procedure is associated with substantial drawbacks, including high mortality and morbidity, as well as a detrimental impact on quality of life when irreversible ostomies necessitate a colostomy bag [5–7].

In the past 2 decades, the use of self-expanding metallic stents (SEMS) has drawn interest since it was first reported in 1991 by Dohmoto for palliation of malignant colonic obstruction [8].

Two randomized trials with 30 and 48 patients comparing surgery to palliative stenting showed similar effectiveness and survival but better quality of life, less peri-interventional morbidity and mortality, and cost-effectiveness in SEMS-treated patients [9, 10].

In contrast, a randomized trial with 21 patients had a high number of serious adverse events in the nonsurgical group (6 perforations in 11 patients), which led to its early closure. This unexpected high rate of perforation may be specifically WallFlex-related or enteral stent-related in patients on chemotherapy [11].

A meta-analysis by Zhao et al. [12] in 2013 showed a significantly higher rate of clinical relief of obstructions in patients submitted to surgery, but in SEMS-treated patients the hospital stay, ICU admission rate, and overall complication rate was lower. The overall survival time was similar. Another meta-analysis by Liang et al. [13] in 2014 revealed that the SEMS group had less successful relief of obstruction, but also lower overall complication and mortality rates.

According to the guidelines of the European Society of Gastrointestinal Endoscopy [14], SEMS placement is the preferred treatment for palliation in malignant colonic obstruction.

Factors likely to influence the initial success of SEMS include the site of obstruction, the length of the obstruction, stent characteristics, and the insertion technique employed [15].

The aim of this study was to evaluate predictive clinical factors for complications and mortality in patients treated with SEMS for palliation of obstructive colorectal cancer.
Patients and Methods

Patient Selection

Patients submitted to SEMS for palliation of obstructive colorectal cancer from January 2005 to December 2015 were included. Colonic obstruction was diagnosed based on anamnesis (inability to pass stools and air), physical examination, and radiologic features. The assignment of patients to undergo palliative treatment was based on unacceptable surgical risk in view of advanced age or comorbidities, or on the presence of locally advanced disease or distant metastases. Exclusion criteria were low rectal tumors, incomplete data, loss to follow-up, and patients with malignant strictures without obstructive symptoms.

Clinical charts were retrospectively reviewed for patient demographics, Eastern Cooperative Oncology Group (ECOG) stage, location of primary and metastatic disease, length of the tumor (measured by CT scan), cancer stage, palliative chemotherapy, technical success, clinical success, stent diameter and length, complications, duration of hospital stay, re-interventions, morbidity, mortality, and survival.

Table 1. Demographic and clinical characteristics of the patients

| Age, years | 78.9 (11) |
| Sex | |
| Male | 23 (51.1%) |
| Female | 22 (48.9%) |
| ECOG stage | |
| 0 | 0 (0%) |
| 1 | 8 (17.8%) |
| 2 | 5 (11.1%) |
| 3 | 14 (31.1%) |
| 4 | 17 (37.8%) |
| Tumor stage | |
| III | 18 (40.0%) |
| IV | 27 (60.0%) |
| Previous chemotherapy/radiotherapy | 0 (0%) |
| Stenosis location | |
| Rectosigmoid colon | 39 (86.7%) |
| Splenic flexure | 2 (4.4%) |
| Transverse colon | 1 (2.2%) |
| Hepatic flexure | 3 (6.7%) |
| Stenosis length, cm | 58.3 (23.6) |
| Duration of hospitalization, days | 5.5 [3-10] |
| Follow-up until death or complication, days | 36.5 [12.25-137.5] |
| Patients with complications during follow-up | 8 (19%) |
| Deaths during follow-up | 38 (84.4%) |
| Patients without complications and alive at the end of follow-up | 6 (13.3%) |

Values are presented as n (%), mean (SD), or median [interquartile range].
ECOG, Eastern Cooperative Oncology Group.

Technique and Stents

All SEMS were placed under endoscopic and fluoroscopic guidance, by gastroenterologists with experience in more than 20 colonic stent placements. Hanarostent® stents (M.I. Tech., Seoul, Korea) 22–24 mm in diameter and 80–140 mm in length were used. Correct positioning was confirmed using both fluoroscopy and endoscopy. Balloon pre-dilation was not performed in any case.

Outcomes

The primary endpoints included survival as well as complication-free survival and its predictors. Complications were defined as events that led to re-intervention, required patient admission to the hospital, or caused death, and included perforation, migration, and obstruction. They were further classified as early if they occurred within 30 days of palliative stenting and late if they occurred after 30 days.

The secondary endpoints included technical success, clinical success, and stent patency. Technical success was defined as successful deployment of the stent across the stricture, and clinical success was defined as relief of obstructive symptoms within 24 h after stent placement. Stent patency was defined as the period between stent placement and recurrence of obstructive symptoms due to obstruction or migration.

Follow-Up

Follow-up data were obtained by reviewing patients’ charts for complications, re-interventions, hospital admissions, and death. Patients were followed until death or if alive until the date of data collection (February 2016).

Statistical Analysis

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) program version 20 (IBM Corp., Armonk, NY, USA).

Categorical variables are presented as frequencies and percentages and continuous variables as means and standard deviations or medians and interquartile ranges in the case of skewed distributions. χ² test or Fisher test and Student t test were used to compare noncontinuous and continuous data, respectively.

Survival, progression-free survival, complication-free survival, and stent patency over time were calculated using the Kaplan-Meier method. Data were censored at the time of endpoint achievement or at the end of follow-up. Categorical predictors of survival were compared using the log-rank test and continuous predictors of survival were evaluated using the Cox proportional hazard model.

Age, sex, ECOG stage, location and stage of the tumor, presence of metastasis, previous chemotherapy, and stenosis length were the variables included in the analysis. A p value <0.05 was considered statistically significant.

Results

Patients and Demographics

From January 2005 to December 2015, 45 patients were eligible for this study. Their demographic and clinical characteristics are summarized in Table 1.
Technical and Clinical Success

SEMS insertion was technically successful in 97.8% (n = 44) and clinically successful in 95.6% (n = 43). The reason for the only case of technical failure was the inability to pass the guidewire across the strictured segment. The patient underwent successful emergent surgery with colostomy. One patient did not experience resolution of symptoms within 72 h after intervention, but no re-intervention was performed since he died from pulmonary embolism.

Long-Term Success

Relief of obstruction without intervention was maintained from stent insertion until death in 35 of 45 patients (77.8%) and in 35 of 43 patients who had immediate clinical success (81.4%). Relief of obstruction without surgery, but requiring a second stent, was maintained until death in 39 of 45 patients (86.7%) and in 39 of 43 patients (90.7%), respectively.

Loss of stent patency occurred in 4 of 45 patients (8.9%) as a result of stent dysfunction (2 stent obstructions and 2 migrations). At 180 days, stent patency was present in 84.2% of the patients. Stent patency over time is depicted in Figure 1a.

Complications and Survival

In the early post-procedure period, 3 patients developed symptoms and radiologic evidence suggestive of perforation that led to death (mean interval of 5 days after SEMS placement). One patient presented with obstructive symptoms 2 days after SEMS placement caused by

---

**Table 2. Early and late complications**

<table>
<thead>
<tr>
<th></th>
<th>Early complications</th>
<th>Late complications</th>
<th>Overall complications</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perforation</td>
<td>3</td>
<td>1</td>
<td>4 (8.9%)</td>
<td>death (3), surgery (1)</td>
</tr>
<tr>
<td>Obstruction</td>
<td>1</td>
<td>1</td>
<td>2 (4.4%)</td>
<td>new SEMS (2)</td>
</tr>
<tr>
<td>Migration</td>
<td>0</td>
<td>2</td>
<td>2 (4.4%)</td>
<td>new SEMS (2)</td>
</tr>
</tbody>
</table>

SEMS, self-expanding metallic stent.

**Table 3. Predictors of complications and mortality (p values)**

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Complications</th>
<th>Complication-free survival</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.294</td>
<td>0.374</td>
<td>0.343</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>0.698</td>
<td>0.918</td>
<td>0.164</td>
</tr>
<tr>
<td>Location (right/left)</td>
<td>1.000</td>
<td>0.177</td>
<td>0.404</td>
</tr>
<tr>
<td>Stage (III/IV)</td>
<td>0.690</td>
<td>0.803</td>
<td>0.261</td>
</tr>
<tr>
<td>Metastasis (yes/no)</td>
<td>0.240</td>
<td>0.391</td>
<td>0.296</td>
</tr>
<tr>
<td>Length of stenosis</td>
<td>0.012*</td>
<td>0.014*</td>
<td>0.807</td>
</tr>
<tr>
<td>ECOG stage</td>
<td>0.676</td>
<td>0.311</td>
<td>0.235</td>
</tr>
<tr>
<td>Complication (yes/no)</td>
<td>–</td>
<td>–</td>
<td>0.984</td>
</tr>
</tbody>
</table>

* Statistically significant (p < 0.05).

---

**Fig. 1. a** Kaplan-Meier curve showing cumulative stent patency over time. **b** Kaplan-Meier curve showing complication-free survival.
kinking of the stent, which was resolved endoscopically by placement of a new stent.

Four patients had late complications, including 1 perforation (41 days after requiring surgical management), 1 obstruction (36 days after requiring surgical management), and 2 migrations (180 and 440 days after requiring surgical management), requiring new endoscopic procedures with stent placement in all 3 cases (Table 2). Complication-free survival was 74.2% at 180 days (Fig. 1b). Overall, only 5 patients had a re-intervention (11.1%), including 4 endoscopic (8.9%) and 1 surgical intervention (2.2%).

Gender, ECOG stage, location of the tumor, and presence of metastasis were not statistically significant predictors of complication-free survival ($p \geq 0.05$). The length of the stenosis was superior in patients with a lower complication-free survival (74.3 vs. 53.7 mm, $p = 0.01$). Likewise, only the length of the stenosis was associated with the presence of complications ($p = 0.01$), as seen in Table 3.

The median length of hospital stay after SEMS insertion was 5 days. The 30-day mortality rate was 37.2%, the 60-day mortality rate 61.3%, and the 1-year mortality rate 87.9% (Fig. 2).

There were no predictors of survival, including age, sex, stage of the tumor, length of the stenosis, presence of metastasis (Fig. 3a), or complications of the procedure (Fig. 3b). The $p$ values for predictors of complications and mortality are summarized in Table 3.
Discussion and Conclusions

Colonic obstruction is a condition with high morbidity and mortality because of the generally poor condition of these patients [16].

Prospective studies, retrospective studies, and previously addressed randomized trials that compare palliation approaches (SEMS versus decompressive colostomy/ileostomy) present contradictory findings and a significant heterogeneity regarding tumor location, staging, study design, follow-up, and overall morbidity [9–11].

Some suggest that palliative SEMS does not have a significant advantage over palliative surgery for decompressing unresectable malignant colorectal occlusion because some patients may have higher survival than expected and consequently more complications and more need for re-interventions. This is mainly due to late complications, suggesting that patients with incurable obstructing colorectal cancer should be offered other treatments different from SEMS, especially if eligible for chemotherapy [17, 18]. On the other hand, others demonstrate shorter hospital stay, comparable risk of short-term complications and mortality, and cost-effectiveness [8, 12]. Sustained relief of obstructive symptoms without re-intervention is an important outcome, and several studies show that long-term clinical efficacy of SEMS can be maintained until death in the great majority of patients [19–21].

In this study, a high technical and clinical success rate for SEMS insertion was demonstrated, since only 1 patient did not achieve decompression despite successful stent deployment. Although the majority of SEMS procedures were performed in the rectosigmoid colon, right colonic obstruction was also managed endoscopically without increased complications.

The perforation rate was of 8.9%, comparable to previous studies where the perforation rate ranged between 0 and 12.8% [14, 15]. Accumulating data suggest a significantly increased risk of perforation in patients receiving bevacizumab, although in this study no patients were submitted to this drug [22]. The stent migration rate was 4.4%, also comparable to previously described rates (0–4.9%) [6, 14].

Despite the potential for complications, this series confirms that the majority of patients can be managed successfully without surgery, since relief of obstruction without surgery was maintained from stent insertion until death in 86.7% of patients.

The length of the stenosis was the only independent predictor associated with lower complication-free survival. This may be an important factor when considering SEMS placement or surgery.

The high mortality rates in this study were probably a consequence of poor patient condition, including advanced age (median age 78.9 years), advanced colorectal cancer (mainly stage IV), and multiple comorbidities (mainly ECOG stage 4), since complications of SEMS insertion were not a significant predictor of mortality.

With the increasingly aggressive surgical management of metastases with curative intent, the characteristics of the patients selected for stenting in this cohort may have changed over the study interval and will continue to evolve [23].

The weaknesses of this study include its retrospective nature, the small number of patients from a single institution, and lack of control group, although a control group in this subset of patients would not be ethically feasible [14].

In conclusion, SEMS placement is a viable intervention for malignant large bowel obstruction. With careful patient selection and appropriately experienced endoscopists, technical and clinical success rates should be high and perforation rates should be low.

Statement of Ethics

This study did not require informed consent nor review/approval by the appropriate ethics committee.

Disclosure Statement

The authors have no conflicts of interest to declare.

References


DOI: 10.1159/000452697

GE Port J Gastroenterol 2017;24:122–128

Sousa/Proença/Silva/Ponte/Rodrigues/Carvalho

128